Fundraising Fox
/Companies
Sign in

Artica Therapeutics

Founded 2020 · 19 employees on LinkedIn · 7 known investors

Find your way into Artica Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

270 people can intro you to Tjeerd

Ask Edward van Wezel to introduce you to Tjeerd Barf

You →Edward · together at Acerta Pharma BV →Tjeerd

234 people can intro you to Arwin

Ask Jamie Chen to introduce you to Arwin Ridder

You →Jamie · together at Yamanouchi Europe →Arwin

Sign up to find every way you can get introduced to Artica Therapeutics

  • Your email: who you already know at Artica Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Artica Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.

BiotechDeep TechHealthtech

Founders & leadership

Artica Therapeutics was founded in 2020 by Tjeerd Barf, Arwin Ridder, and Ad IJzerman.

TBTjeerd Barf
Tjeerd BarfCo-founder & CEOTjeerd Barf brings over 25 years of pharmaceutical research and development experience across startup and large-cap organizations, with expertise in metabolic disease, immunology, and oncology. He specializes in covalent chemistry drug discovery, medicinal chemistry, and structure-based drug design for kinase and protease targets.
ARArwin Ridder
Arwin RidderCo-founder & COOArwin Ridder is co-founder and COO of Artica Therapeutics, which develops small molecule inhibitors for autoimmune and inflammatory conditions. He has worked as a drug developer and project leader on complex pharmaceutical programs.
AI
Ad IJzermanCo-founder & SAB Chair
JJason
JasonChief Scientific OfficerJason has held senior leadership positions in life sciences for over 30 years, with expertise spanning drug discovery, development, and clinical advancement across immunology, oncology, and neuroscience. He has directed multidisciplinary teams from target validation through Phase 2 clinical development and has experience in medical device development and venture capital.

Investors · 7

Thuja Capital✓ confirmed by Artica TherapeuticsUtrecht

How we know: the company's own site · funding news · biogenerationventures.com · Not right? Tell us

Seroba Life Scienceslisted by Seroba Life SciencesDublin · $540K – $7.6M

How we know: a partner's Signal profile · Not right? Tell us

BGVreportedSilicon Valley

How we know: biogenerationventures.com · Not right? Tell us

Also in the syndicate · 3

Innovation QuarterInnovationQuarterSerobalead

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Artica Therapeutics do?
Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.
Who founded Artica Therapeutics?
Artica Therapeutics was founded by Tjeerd Barf, Arwin Ridder, Ad IJzerman in 2020.
Who are Artica Therapeutics's investors?
Artica Therapeutics's investors include BioGeneration Ventures, Thuja Capital, Seroba Life Sciences, BGV.